Sensex & Nifty tank 1.5% as Vedanta adjusts for demerger and HUL slips post-Q4. Bajaj Finance defies the trend—here is…
The biggest opportunities are often hidden in oversold markets. When momentum begins to reverse, early strength begins to build underneath.…
India’s ₹10,000 crore Biopharma SHAKTI scheme marks a definitive shift from low-cost generics to high-value biologics, aiming to integrate local…
India’s Testing, Inspection, and Certification (TIC) market is projected to hit $10.9 billion by 2034, driven by stringent regulations in…
Let’s take a look at 5 best CDMO pharma stocks in India.
Nuvama has flagged four pharma stocks as top ‘Buy’ picks, citing strong US launches, biosimilars traction and margin expansion with…
JPMorgan says India’s CRDMO market will grow to $15.4 billion by 2029, driven by China+1, regulatory edge and cost advantage,…
India’s CDMO sector is rapidly expanding, driven by global pharma’s shift away from China, strong regulatory compliance, cost-efficiency, and government…
The world’s largest sovereign wealth fund that manages over US$ 1 Trillion in assets and that made profits of US$222…
Investors are closely monitoring the performance of Indian pharma companies in the March 2025 quarter and their ability to grow…
Syngene share price today, April 24: Syngene’s stock drops 13% due to 8% Q4 profit decline. Explore insights into their…
Kotak Institutional Equities recommends Piramal Pharma, Syngene International, and Indegene as top buys, citing strong growth potential in CRDMOs, pharmaceutical…
Stocks to watch today, March 11: GIFT Nifty was trading lower at 22,363, which indicates a negative start for domestic…
Reportedly, the company has plans to inject Rs 788 crore and create 1,000 additional jobs in the project over the…
Hunt said that in Manufacturing, the highlight of the quarter was the successful inspection of our biologics facilities by the…
The first quarter results were against a strong quarter last year due to sales of COVID treatment, Remdesivir. Excluding the…
Macquaries sees Divi’s Laboratories and Syngene International as well placed in terms of growth, margin profile and return ratios
Revenue grows 31 per cent to Rs 334 crore; EBITA up by 23 per cent to Rs 106 crore